[Skip to Navigation]
Views 8,443
Citations 0
JAMA Clinical Guidelines Synopsis
February 2, 2021

Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy

Author Affiliations
  • 1University of Chicago, Chicago, Illinois
  • 2Hospital for Special Surgery, Weill Cornell Medicine, New York, New York
JAMA. 2021;325(5):482-483. doi:10.1001/jama.2020.17308

ICIs are monoclonal antibodies that block inhibitory regulatory proteins. Their use leads to T-cell activation, engaging the immune system to treat the malignancy.2 ICI toxicities, known as IRAEs, range from mild skin rash to fatal myocarditis.3 There are no clinical trials to guide IRAE management, and treatment is based on management of autoimmune diseases outside the ICI setting.